Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotetinib in RET-altered Advanced Solid Tumors
NCT05278364Phase 2Unknown
- Sponsor
- Shouyao Holdings
- Start
- Apr 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sotetinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), solid tumor, sponsored by Shouyao Holdings. Status: unknown.
02
Drugs
sotetinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)solid tumor
Beyond the preview
Go deeper on NCT05278364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278364.